The use of leflunomide in the treatment of rheumatoid arthritis: An experimental and clinical review

Immunopharmacology

Volumn 47, Issue 2-3, 2000, Pages 291-298

  Schattenkirchner, Manfred ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

DMARDs; Leflunomide; Methotrexate; Rheumatoid arthritis; Sulfasalazine

Indexed keywords

LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE;

ALOPECIA; CLINICAL TRIAL; DRUG SAFETY; GASTROINTESTINAL TOXICITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TOXICITY; PHASE 3 CLINICAL TRIAL; PHYSICAL DISEASE BY BODY FUNCTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE ACTIVATION;

EID: 0034084212     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0162-3109(00)00194-6     Document Type: Article

References (27)

1. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., Healey L.A., Kaplan S.R., Liang M.H., Luthra H.S., Medsger T.A. Jr., Mitchel D.M., Neustadt D.M., Pinals R.S., Schaller J.G., Sharp J.T., Wilder R.L., Hunder G.G. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31:1988;315-324.
2. Bartlett R.R., Schleyerbach R. Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potent antirheumatic activity: I. Disease-modifying action on adjuvant arthritis of the rat. Int. J. Immunopharmacol. 7:1985;7-18.
3. Cherwinski H.M., Byars N., Ballaron S.J., Nakano G.M., Young J.M., Ransom J.T. Leflunomide interferes with pyrimidine nucleotide biosynthesis. Inflammation Res. 44:1995;317-322.
4. Cherwinski H.M., Cohn R.G., Cheung P., Webster D.J., Xu Y.Z., Caulfield J.P., Young J.M., Nakano G., Ransom J.T. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J. Pharmacol. Exp. Ther. 275:1995;10443-10449.
5. Emery P., Breedveld F., Lemmel E.M., Rosenburg R., LoewFriedrich I. A Phase III, randomized, double-blind study of leflunomide versus methotrexate in rheumatoid arthritis. Ann. Rheum. Dis. 1999;103.
6. Fairbanks L.D., Bofill M., Rückemann K., Simmonds H.A. Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors. J. Biol. Chem. 270:1995;29682-29689.
7. Felson D.T., Anderson J.J., Boers M., Bombardier C., Chernoff M., Fried B., Furst D., Goldsmith C., Kieszak S., Lightfoot R., Paulus H., Tugwell P., Weinblatt M., Widmark R., Williams H.J., Wolfe F. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum. 36:1993;729-740.
8. Fox R.I. Mechanism of action of leflunomide in rheumatoid arthritis. J. Rheumatol. 25(Suppl. 53):1998;S20-S26.
9. Glant T.T., Mikecz K., Bartlett R.R., Deak F., Thonar E.J., Williams J.M., Mattar T., Kuettner K.E., Schleyerbach R. Immunomodulation of proteoglycan-induced progressive polyarthritis by leflunomide. Immunopharmacology. 23:1992;105-116.
10. Glant T.T., Mikecz K., Brennan F., Negrolu G., Bartlett R.R. Suppression of autoimmune responses and inflammatory events by leflunomide in an animal model for rheumatoid arthritis. Agents Actions. 41:1994;C267-C270.
11. Hambleton P., McMahon S. Drug actions on delayed-type hypersensitivity in rats with developing and established adjuvant arthritis. Agents Actions. 29:1990;328-332.
12. Harris E.D. Rationale for combination therapy of rheumatoid arthritis based on pathophysiology. J. Rheumatol. 23(Suppl. 44):1996;2-4.
13. Kalden J.R., Smolen J.S., Rozman B., Scott D.L., Strand V., Loew-Friedrich I., Rosenburg R. Leflunomide vs. placebo vs. sulfasalazine in rheumatoid arthritis: impact on functional ability. Ann. Rheum. Dis. 213:1999.
14. Larsen A., Emery P., Kalden J.R., Loew-Friedrich I., Rosenburg R. Comparison of radiographic endpoints in rheumatoid arthritis patients treated with leflunomide or methotrexate. Ann. Rheum. Dis. (Suppl.). 1999;31.
15. Larsen A., Smolen J.S., Kalden J.R., Rozman B., Scott D.L., Loew-Friedrich I., Rosenburg R. Radiographic analysis of disease progression with leflunomide vs. placebo vs. sulfasalazine in rheumatoid arthritis. Ann. Rheum. Dis. (Suppl.). 1999;209.
16. Mladenovic V., Domljan Z., Rozman B., Diadic I., Mihajlovic D., Dordevic J., Popovic M., Dimitrijevic M., Zivkovic M., Campion G., Musikic P., Loew-Friedrich I., Oed C., Seifert H., Strand V. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis: results of a randomized, placebo-controlled, phase II study. Arthritis Rheum. 38:1995;1595-1603.
17. Moreland L.W., Fleischmann R.M., Strand V. Efficacy of leflunomide vs. placebo vs. methotrexate in early and late rheumatoid arthritis. Arthritis Rheum. 9:1998;S155. (Suppl.).
18. Pasternak R.D., Wadopian N.S., Wright R.N., Siminoff P., Gylys J.A., Buyniski J.P. Disease-modifying activity of HWA 486 in rat adjuvant-induced arthritis. Agents Actions. 21:1987;241-243.
19. Pham B., Cranney A., Boers M., Verhoeven A.C., Wells G., Tugwell P. Validity of area-under-the-curve analysis to summarize effect in rheumatoid arthritis clinical trials. J. Rheumatol. 27:1999;712-716.
20. Pinals R.S., Masi A.T., Larsen R.A. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum. 24:1981;1308-1315.
21. Rückemann K., Fairbanks L.D., Carrey E.A., Hawrylowicz C.M., Richards D.F., Kirschbaum B., Simmonds H.A. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans. J. Biol. Chem. 273:1998;21682-21691.
22. Smolen J.S., Kalden J.R., Scott D.L., Rozman B., Kvien T.K., Larsen A., Loew-Friedrich I., Oed C., Rosenburg R. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet. 353:1999;259-266.
23. Smolen J.S., Scott D.L., Kalden J.R., Rozman B., Strand V., Loew-Friedrich I., Rosenburg R. A randomized, double-blind study of leflunomide vs. sulfasalazine in rheumatoid arthritis: 1-year update. Annals Rheum. 1999;103.
24. Strand V., Cohen S., Schiff M., Weaver A., Fleischmann R., Cannon G., Fox R., Moreland L., Olsen N., Furst D., Caldwell J., Kaine J., Sharp J., Hurley F., Loew-Friedrich I. Treatment of active rheumatoid arthritis with leflunomide compared to placebo and methotrexate. Arch Intern. Med. 159:1999;2542-2550.
25. Thoss K., Henzgen P.K., Petrow D., Katenkamp D., Brauer R. Immunomodulation of rat antigen-induced arthritis by leflunomide alone and in combination with cyclosporin A. Inflammation Res. 45:1996;103-107.
26. Weber W., Harnisch L. Use of a population pharmacokinetic model to predict clinical outcome of leflunomide, a new disease-modifying drug in the treatment of rheumatoid arthritis. Aarons L., Balant L.P., Danhof M., Gex-Fabry M., Gundert-Remy U.A., Karlsson M.O., Mentre F., Morselli P.L., Rombout F., Rowland M., Steiner J.L., Vozeh S. European Cooperation in the Field of Scientific and Technical Research. European Commission Directorate-General Science, Research and Development, Brussels. 1997;239-244.
27. Weinblatt M.A., Kremer J.M., Coblyn J.S., Maier A.L., Helfgott H.M., Morrell M., Byrne V.M., Kaymakcian M.V., Strand V. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum. 42:1999;1322-1328.